| Revision as of 20:12, 19 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits ce; templated cites← Previous edit |
Latest revision as of 16:36, 25 December 2024 edit undoRodw (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers773,834 editsm Disambiguating links to McNeil (link changed to McNeil Consumer Healthcare) using DisamAssist. |
| (3 intermediate revisions by 2 users not shown) |
| Line 4: |
Line 4: |
|
| image = Mcn 5707.svg |
|
| image = Mcn 5707.svg |
|
| width = 250px |
|
| width = 250px |
|
| caption = |
|
| caption = |
|
|
|
|
|
<!-- Clinical data --> |
|
<!-- Clinical data --> |
| Line 22: |
Line 22: |
|
| class = |
|
| class = |
|
| ATC_prefix = |
|
| ATC_prefix = |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
|
|
|
|
<!-- Legal status --> |
|
<!-- Legal status --> |
|
| legal_status = |
|
| legal_status = |
|
|
|
|
|
<!-- Pharmacokinetic data --> |
|
<!-- Pharmacokinetic data --> |
| Line 35: |
Line 35: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| duration_of_action = |
|
| duration_of_action = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!-- Identifiers --> |
|
<!-- Identifiers --> |
|
| CAS_number = 96795-88-9 |
|
| CAS_number = 96795-88-9 |
|
|
| CAS_number2 = 109214-56-4 |
|
|
| index2_label = hydrobromide |
|
| CAS_supplemental = |
|
| CAS_supplemental = |
|
| PubChem = 126059 |
|
| PubChem = 126059 |
| Line 47: |
Line 49: |
|
| KEGG = |
|
| KEGG = |
|
| ChEBI = |
|
| ChEBI = |
|
| ChEMBL = |
|
| ChEMBL = 1743803 |
|
| NIAID_ChemDB = |
|
| NIAID_ChemDB = |
|
| PDB_ligand = |
|
| PDB_ligand = |
| Line 59: |
Line 61: |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N |
|
}} |
|
}} |
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980’s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> |
|
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> |
|
|
|
|
|
|
|
|
For related agents, see ], ], ], ] & ]. |
|
For related agents, see ], ], ], ] & ]. |
| Line 76: |
Line 77: |
|
] |
|
] |
|
] |
|
] |
|
|
] |
